Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors.

NCT03889275 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT03889275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03889275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors.
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
October 24, 2019
Completion date
December 12, 2022
Enrollment
39 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors